577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy

checkorphan
Learn more about:
Central serous chorioretinopathy
Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy

Official Title

Prospective Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy

Brief Summary

      The purpose of this study is to determine whether micropulse laser (MPL) is different to
      half-dose photodynamic therapy on acute central serous chorioretinopathy.

Detailed Description

      Central serous chorioretinopathy(CSC) is characterized by serous detachment of neurosensory
      retina which can cause lose in visual acuity.Some studies have shown that Half-dose
      photodynamic therapy(PDT) is effective on CSC,although accompanied with side-effects,such as
      choroidal ischemia, retinal pigmental epithelium(RPE) atrophy,and RPE rip,and with exorbitant
      price.Recent retrospective studies suggest micropulse laser (MPL) therapy may also be
      effective without obvious complications in this disease. But to date, there is no study on
      effectiveness of CSC between PDT and MPL.

      The study is the first prospective randomized controlled trial about 577nm micropulse laser
      versus half-dose photodynamic therapy on acute central serous chorioretinopathy.The null
      hypothesis of the study is that there is difference between MPL and half-dose photodynamic
      therapy on acute central serous chorioretinopathy at first month after treatment.The primary
      outcome measures is the proportion of eyes with complete absorption of subretinal fluid at 1
      month after treatment.

Study Type

Interventional

Primary Outcome

the proportion of eyes with complete absorption of subretinal fluid(SRF)

Secondary Outcome

 Change of Best Corrected Visual Acuity(BCVA)

Condition

Acute Central Serous Chorioretinopathy

Intervention

577-MPL

Study Arms / Comparison Groups

 577-MPL
Description:  577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent "hot spots" on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Device

Estimated Enrollment

68

Start Date

September 2016

Completion Date

December 2019

Primary Completion Date

December 2019

Eligibility Criteria

        Inclusion Criteria:

          1. onset for the first time, as an episode duration of less than 6 months

          2. patient was between 18 and 55 years of age

          3. the presence of subretinal fluid(SRF) involving the macula and detected by use of
             optical coherence tomography (OCT)

          4. active fluorescein leakage during fluorescein angiography (FA)

          5. best corrected visual acuity (BCVA) more than 0.1, and less than 1.0

        Exclusion Criteria:

          1. previous PDT, focal photocoagulation, intravitreal injections of anti-vascular
             endothelial growth factor, or ocular surgery

          2. other macular abnormalities such as choroidal neovascularization(CNV) or polypoidal
             choroidal vasculopathy(PCV)

          3. retinal atrophy

          4. pregnancy

          5. inability to obtain photographs or to perform FA

          6. use of steroid systemically or topically in the last 6 months

Gender

All

Ages

18 Years - 55 Years

Accepts Healthy Volunteers

No

Contacts

Chenjin Jin, ,

Location Countries

China

Location Countries

China

Administrative Informations

NCT ID

NCT02587767

Organization ID

577MPLACS(Marshall Study)

Responsible Party

Principal Investigator

Study Sponsor

Sun Yat-sen University

Study Sponsor

Chenjin Jin, Study Director, Zhongshan Ophthalmic Center, Sun Yat-sen University

Verification Date

April 2022